REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Users\rdesai\Documents\STN Express 8.4\Queries\10581175.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STD
/ Structure 1 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:07:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 637 TO ITERATE

100.0% PROCESSED 637 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11226 TO 14254
PROJECTED ANSWERS: 3709 TO 5531

L2 50 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 14:07:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 13163 TO ITERATE

100.0% PROCESSED 13163 ITERATIONS 5019 ANSWERS
SEARCH TIME: 00.00.01

L3 5019 SEA SSS FUL L1

=>
Uploading C:\Users\rdesai\Documents\STN Express 8.4\Queries\10581175.str

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STD
/ Structure 2 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 14:12:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 637 TO ITERATE

100.0% PROCESSED 637 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11226 TO 14254
PROJECTED ANSWERS: 3421 TO 5179

L5 50 SEA SSS SAM L4

=> s l4
SAMPLE SEARCH INITIATED 14:12:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 637 TO ITERATE

100.0% PROCESSED 637 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11226 TO 14254
PROJECTED ANSWERS: 3421 TO 5179

L6 50 SEA SSS SAM L4

=> file casplus
'CASPLUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> s l6
SAMPLE SEARCH INITIATED 14:13:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 637 TO ITERATE

100.0% PROCESSED 637 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11226 TO 14254
PROJECTED ANSWERS: 3421 TO 5179

L7 50 SEA SSS SAM L4

=> file caplus

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l6
L8 8 L6

-~ d abs bib hitstr 1-8

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
CI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to spiroindolinepiperidine of formula I, which are useful as anthelminthics. Compds. of formula I wherein Y is O and S; O is CH2CH(CH3), CH2CH2O, CH2CH=CH, etc.; R1 is H, F, Cl, etc.; R2 is H, F, CL, etc.; A1 is H, halo and C1-4 alkyl; A2 is H, halo, (un)substituted C1-4 alkyl, etc.; A3 and A4 are independently H, halo, C1-4 alkyl; R1, R4 and R5 are independently H, F, Cl, etc.; R2 is H, F, NO2, etc.; R3 is H, F, CN, etc.; and pharmaceutically acceptable solvates, N-oxides and salts thereof, are claimed. Example compd. II was prepd. by a multistep procedure (procedure given). All the invention compds. were evaluated for their anthelminthic activity (data given).

AN 2011:1000085 CAPLUS <<LOGINID::20111010>>

DN 155:271085

TI Spiroindolinepiperidine derivatives and their preparation and use as anthelminthics

IN Lutz, Juergen; Koch, Sandra; Unhoff, Manfred; Heckeroth, Anja Regina; Oepen Von, Britta; Sondern, Ulrich

PA Intervet International B.V., Neth.

SO PCT Int. Appl., 76pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2011095581	A1	20110811	WO 2011-EP51639	20110204

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, AU, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR, TT, TZ, UG, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI EP 2010-152817 A 20100205
US 2010-302312P P 20100208

OS MARPAT 155:271085

RE ***1322047-88-0P*** ***1322048-37-2P*** ***1322048-73-6P***
1322049-04-6P ***1322049-11-5P***

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of spiroindolinepiperidine derivs. as anthelminthics)

RN 1322047-88-0 CAPLUS

CN Methanone, [5-chloro-1'-[(2E)-3-(2-chlorophenyl)-2-propen-1-yl]-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)

Double bond geometry as shown.

/ Structure 3 in file .gra /

RN 1322048-37-2 CAPLUS
CN Methanone, [5-chloro-1'-[(2E)-3-(3,4-dichlorophenyl)-2-propen-1-yl]-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1-yl](2-fluoro-4-pyridinyl)- (CA INDEX NAME)

Double bond geometry as shown.

/ Structure 4 in file .gra /

RN 1322048-73-6 CAPLUS
CN Methanone, [5-chloro-1'-[(2E)-3-[2-fluoro-4-(trifluoromethyl)phenyl]-2-propen-1-yl]-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)

Double bond geometry as shown.

/ Structure 5 in file .gra /

RN 1322049-04-6 CAPLUS
CN Methanone, [1'-[(2E)-3-(4-chloro-2-fluorophenyl)-2-propen-1-yl]-1,2-dihydro-5-methoxyspiro[3H-indole-3,4'-piperidin]-1-yl](2-chloro-4-pyridinyl)- (CA INDEX NAME)

Double bond geometry as shown.

/ Structure 6 in file .gra /

RN 1322049-11-5 CAPLUS
CN Methanone, (2-chloro-4-pyridinyl)[5-methyl-1'-[(2E)-3-[4-(trifluoromethyl)phenyl]-2-propen-1-yl]spiro[3H-indole-3,4'-piperidin]-1(2H)-yl]- (CA INDEX NAME)

Double bond geometry as shown.

/ Structure 7 in file .gra /

RE CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
CI

/ Structure 8 in file .gra /

AB The invention relates to spiropiperidine derivs. of formula I, which are GPR40 agonists and which are useful in the treatment of diabetes. Compds. of formula I wherein R1 is H, F and Cl; R2 is H, C1-3 alkyl, CF3, methoxy, F and Cl; R4 and R4a are independently H, C1-3 alkyl, CF3, methoxy and F; provided that at least one of R4 and R4a is H; R5 is H and 1-propynyl; X is CHR3CH2, CR3=CH, C(O)CH2, etc.; R3 is H and C1-3 alkyl; and pharmaceutically acceptable salts thereof, are claimed. Example compd. II was prepd. by a multistep procedure (procedure given). All the invention compds. were evaluated for their GPR40 agonistic activity. From the assay, it was detd. that compd. II exhibited an EC50 value of 186.+-.93 nM with 91 +- 10% efficacy.
AN 2011:498231 CAPLUS <<LOGINID::20111010>>
DN 154:486226

TI Spiropiperidine derivatives as GPR40 agonists and their preparation and use for the treatment of diabetes
IN Hamdouchi, Chafiq; Tiwaswala, Jayana Pankaj; Maiti, Pranab
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 73pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO	KIND	DATE	APPLICATION NO	DATE
PI	WO 2011046851	A1	20110421	WO 2010-US52126	20101011
	W: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW				
	RW: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG BW GH GM KE LR LS MW MZ NA, SD, SL, SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM				
	US 20110092531	A1	20110421	US 2010-901597	20101011
PRAI	US 2009-251839P	P	20091015		
	US 2010-303234P	P	20100211		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 154:486226; MARPAT 154:486226
TT ***1292290-93-7P*** ***1292291-63-4P*** ***1292291-81-6P***
PL; PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preprn. of spiropiperidine derivs. as GPR40 agonists useful in the treatment of diabetes)
RN 1292290-93-7 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 7-chloro-1,2-dihydro-1-methyl- (CA INDEX NAME)

/ Structure 9 in file .gra /

RN 1292291-63-4 CAPLUS
CN Benzenepropanoic acid, 4-[[4-[[1,2-dihydro-1-methyl-5-(trifluoromethyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]methyl]phenyl]methoxy]-2-fluoro-, ethyl ester (CA INDEX NAME)

/ Structure 10 in file .gra /

/ Structure 11 in file .gra /

RN 1292291-81-6 CAPLUS
CN Benzenepropanoic acid, 4-[[4-[[1,2-dihydro-1,5-dimethylspiro[3H-indole-3,4'-piperidin]-1'-yl)methyl]phenyl]methoxy]-2-fluoro-, ethyl ester (CA INDEX NAME)

/ Structure 12 in file .gra /

/ Structure 13 in file .gra /

RE CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
CI

/ Structure 14 in file .gra /

AB The invention is related to the prepn. of spiro compds. I [X3 and X4 = CH2 and CH2, CH2 and CO, CO and CH2; Y1 and Y2 = any of X3 and X4, CH2 and S, SO2 and CH2, NH and CO, etc.; R1 = aminoalkyl (hetero)arylcarbonylaminoalkyl, aminosulfonylaminoalkyl, etc., wherein each instance of aryl is optionally substituted wit 1-2 halo substituents; R2 = absent, one halo substituent; R3 = H, alkylaryl-R5, CONR5, SO2R5; R5 = haloaryl, nitroarylalkyl, aminoheteroarylthio, alkoxyheteroaryl, etc.], particularly spiropiperidines, as tryptase inhibitors. Thus, spiropiperidine II was prepd. by a multi-step synthesis from 1-(tert-butoxycarbonyl)-4-piperidone and studied in a beta-tryptase in-vitro enzyme assay, in an antigen-induced allergic sheep model of asthma, and in a guinea pig model of allergic asthma. I are useful for treating a tryptase mediated inflammatory, vascular or dermatol. condition.

AN 2009:649329 CAPLUS <<LOGINID::20111010>>
DN 151:8305
TI Preparation of spiropiperidines as tryptase inhibitors
IN Costanzo, Michael J.; Yabut, Stephen C.; Tounge, Brett; Maryanoff, Bruce E.; Zhang, Han-Cheng
PA Janssen Pharmaceutica, N.V., Belg.
SO PCT Int. Appl., 291pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1

	PATENT NO	KIND	DATE	APPLICATION NO	DATE
PI	WO 2009067202	A1	20090528	WO 2008-US12899	20081119
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	CA 2706391	A1	20090528	CA 2008-2706391	20081119
	US 20090163527	A1	20090625	US 2008-313289	20081119
	EP 2224803	A1	20100908	EP 2008-853021	20081119
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,				

SK, TR, AT, BA, MK, RS
PI EP 2011504499 T 20110210 EP 2010-534955 20081119
PRAI US 2007-3970P P 20071121
WO 2008-US12899 W 20081119
OS CASREACT 151:8305; MARPAT 151:8305
ST ***1159093-65-8P***
PT, PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of spiropiperidines as tryptase inhibitors)
RN 1159093-65-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1(2H)-acetic acid, 5-(aminomethyl)-.alpha.-oxo-1'-[[5-(2-phenylethynyl)-2-furanyl]carbonyl]-, ethyl ester (CA INDEX NAME)

/ Structure 15 in file .gra /

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
CI

/ Structure 16 in file .gra /

AB Title compds. I [R1 = 2-oxopiperidines with provisos; R2 = H, F, CN, etc.; R3 = H, alkylene, etc.; R4 = H, alkylene, etc.; U = N, N-oxide, CR10; V = N, N-oxide, CR11; X = N, N-oxide, CR12; Y = N, CR13; R10 = H, halo, CN, etc.; R11 = H, Cl, alkyl, etc.; R12 = H, halo, CN, etc.; R13 = H, halo, alkyl] and their pharmaceutically acceptable salts and formulations were prepd. For example, coupling of acid II and 2,3-dihydro-1H-indole afforded claimed. In CGRP receptor antagonists assays, 9-examples of compds. I exhibited Ki values ranging from 2-690 nM.
AN 2009:646132 CAPLUS <<LOGINID::20111010>>
DN 151:8303
TI Preparation of as piperidinobenzamides CGRP receptor antagonists
IN Gottschling, Dirk; Dahmann, Georg; Doods, Henri; Heimann, Annekatrin; Mueller, Stephan Georg; Rudolf, Klaus; Schaenzle, Gerhard; Stenkamp, Dirk
PA Boehringer Ingelheim International GmbH, Germany
SO PCT Int. Appl., 399pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009065919	A2	20090528	WO 2008-EP65960	20081121
WO 2009065919	A3	20091001		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,

TG, BW, CH, CM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2705405 A1 20090528 CA 2008-2705405 20081121
EP 2225223 A2 20100908 EP 2008-851956 20081121
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, AL, BA, MK, RS
EP 2251338 A2 20101117 EP 2010-172020 20081121
EP 2251338 A3 20110608
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, AL, BA, MK, RS
JP 2011504478 T 20110210 JP 2010-534484 20081121
US 20110195954 A1 20110811 US 2010-743004 20100913
PRAI EP 2007-121347 A 20071122
EP 2008-851956 A3 20081121
WO 2008-EP65960 W 20081121

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 151:8303

TI ***1159008-73-7D***
DT.CA CAplus (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(prepn. of as piperidinobenzamides CGRP receptor antagonists)

RN 1159008-73-7 CAPLUS

CN 2H-Imidazo[4,5-b]pyridin-2-one, 1-[1-[6-[(1,2-dihydro-1'-methylspiro[3H-
indole-3,4'-piperidin]-1-yl)carbonyl]-4-pyrimidinyl]-4-piperidinyl]-1,3-
dihydro- (CA INDEX NAME)

/ Structure 17 in file .gra /

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
CI

/ Structure 18 in file .gra /

AB This invention relates to compds. of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compns. thereof which are useful for the therapeutic treatment of diseases assocd. with the modulation or inhibition of 11 beta -HSD1 in mammals. The invention further relates to pharmaceutical compns. of the compds. and methods for their use in the regn. or control of the prodn. of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. Compds. of formula I wherein K, L, M, X and Y are independently C, N and O, provided that the total no. of O and N in the ring is 3 or less and when K, L, M, X and Y is O, any adjacent atoms in the ring cannot be O, dotted line is single and double bonds, A and B are independently CH2 and CH2CH2, R1 - R5 are independently H, (un)substituted (hetero)aryl, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted cycloalkyl, (un)substituted arylalkyl, etc. when K, L, M, X and Y is -O- and -N- then p1, p2, p3, p4 and p5, resp. is 0. when K, L, M, X and Y is -N- and -C- then p1, p2, p3, p4 and p5, resp. is 1. when K, L, M, X and Y is -C- and R1, R2, R3, R4, and R5 is connected through a double bond, then p1, p2, p3, p4 and p5, resp. is 1; Q is O and NH and derivs.; R7 is

(un)substituted satd. C7-12 (hetero)bicycloalkyl and (un)substituted satd.
C9-12 (hetero)tricycloalkyl, and their enantiomers, diastereoisomers,
geometrical isomers, and pharmaceutically acceptable salts thereof, are
claimed. Example compd. II was prepd. by acylation of tert-Bu
spiro[indoline-3,4'-piperidine]-1-carboxylate followed by amidation with
2-aminoadamantane hydrochloride. All the invention compds. were evaluated
for their 11 beta -HSD1 inhibitory activity (data given).

AN 2008:256101 CAPLUS <<LOGINID::20111010>>

DN 148:308196

TI Azaspirocyclic compounds as inhibitors of 11 beta -hydroxysteroid dehydrogenase type 1 and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Claremon, David A.; Singh, Suresh B.; Tice, Colin M.; Ye, Yuanjie; Caggiano, Salvacion; He, Wei; Simpson, Robert; Xu, Zhenrong; Zhao, Wei

PA Vitae Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 225 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008024497	A2	20080228	WO 2007-US18789	20070824
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	CA 2661503	A1	20080228	CA 2007-2661503	20070824
	EP 2064187	A2	20090603	EP 2007-837345	20070824
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2010501578	T	20100121	JP 2009-525653	20070824
	US 20110034455	A1	20110210	US 2009-310457	20090903
PRAI	US 2006-840203P	P	20060825		
	WO 2007-US18789	W	20070824		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 148:308196; MARPAT 148:308196

TT ***1017541-10-4P*** ***1017541-37-5P*** ***1017541-88-6P***
1017541-99-8P ***1017542-29-8P*** ***1017542-43-6P***
RL: BAC (Biological activity or effector, except adverse); BPRH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prophetic drug candidate; prepn. of azaspirocyclic compds. as 11 beta -HSD1 inhibitors useful in the treatment of diseases)

RN 1017541-10-4 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid, 1-(2,2-dimethyl-1-oxopropyl)-1,2-dihydro-, 5-(aminocarbonyl)tricyclo[3.3.1.13,7]dec-2-yl ester (CA INDEX NAME)

/ Structure 19 in file .gra /

RN 1017541-37-5 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1,1'(2H)-dicarboxylic acid, 5-(trifluoromethyl)-, 1-(1,1-dimethylethyl) 1'-tricyclo[3.3.1.13,7]dec-2-yl ester (CA INDEX NAME)

/ Structure 20 in file .gra /

RN 1017541-88-6 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, 1-acetyl-1,2-dihydro-N-[5-(hydroxymethyl)tricyclo[3.3.1.13,7]dec-2-yl]- (CA INDEX NAME)

/ Structure 21 in file .gra /

RN 1017541-99-9 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid, 1-acetyl-1,2-dihydro-, 5-(hydroxymethyl)tricyclo[3.3.1.13,7]dec-2-yl ester (CA INDEX NAME)

/ Structure 22 in file .gra /

RN 1017542-29-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxamide, N-[5-(aminosulfonyl)tricyclo[3.3.1.13,7]dec-2-yl]-1,2-dihydro-1-methyl- (CA INDEX NAME)

/ Structure 23 in file .gra /

RN 1017542-43-6 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid, 1,2-dihydro-1-methyl-, 5-(aminosulfonyl)tricyclo[3.3.1.13,7]dec-2-yl ester (CA INDEX NAME)

/ Structure 24 in file .gra /

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
AI

/ Structure 25 in file .gra /

AB Compds. and pharmaceutically acceptable salts of the compds. are disclosed, wherein the compds. have the structure of formula I as defined in the specification. Corresponding pharmaceutical compns., methods of treatment, methods of synthesis, and intermediates are also disclosed. Compds. of formula I wherein Y1 is CR7, Y2 is CR4, Y3 is CR6, Y4 is (CHR9)0-2, Y5 is CH2, CH2CH2, Y8 is CR3, R1, R2, R3, R4 and R6 are independently H, halo, CN, OH and derivs., alkyl, alkenyl, etc., R7 is H, halo, OH, alkyl, alkoxy, CN and alkyl-CO, R5, R8 and R9 are independently halo, CN, OH and derivs., CO2H and derivs., NH2 and derivs., H, alkyl, alkenyl, etc., R11, R12, R13 and R14 are independently halo, CN, H, CO2H and derivs., CONH2 and derivs., OH and derivs., NH2 and derivs., alkyl,

etc., R17 is (un)substituted alkyl, (un)substituted alkenyl, (un)substituted cycloalkyl, and (un)substituted cycloalkenyl; R18 is H, halo, and alkyl; R19 are H; R18R19 taken together to form =O; and their pharmaceutically acceptable salts thereof, are claimed. Example compd. TT hydrochloride was prepd. by reductive alkylation of 4-(2-methoxy-4-trifluoromethylphenyl)piperidine hydrochloride with 1-methyl-1H-benzo[d]imidazole-2-carboxaldehyde. All the invention compds. were evaluated for their ability to potentiate mGluR2. From the assay, it was detd. that compd. TT exhibited EC50 value of < 0.0193 .mu.M.

AN 2008:123519 CAPLUS <<LOGINID::20111010>>

DN 148:215048

TI Benzimidazolyl compounds as potentiators of mGluR2 subtype of glutamate receptor and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Efremov, Ivan Viktorovich; Rogers, Bruce Nelsen; Duplantier, Allen Jacob; Zhang, Lei; Zhang, Qian; Maklad, Noha Serour; Evrard, Edelweiss Virginie; Brodney, Michael A

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 170pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008012623	A1	20080131	WO 2007-IB2032	20070712

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2007278199 A1 20080131 AU 2007-278199 20070712

US 20080280933 A1 20081113 US 2007-780579 20070720

PRAI US 2006-833149P P 20060725

OS CASREACT 148:215048; MARPAT 148:215048

TI ***1004614-45-2P*** ***1004614-75-8P*** ***1004615-29-5P*** ***1004615-32-9P*** ***1004615-56-8P***

IT., PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of benzimidazolyl compds. as potentiators of mGluR2 or glutamate receptor useful in treatment and prevention of diseases)

RN 1004614-45-2 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1(2H)-butanoic acid, 5-methyl-1'-[(1-methyl-1H-benzimidazol-2-yl)methyl]-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 26 in file .gra /

RN 1004614-75-8 CAPLUS

CN 1-Butanone, 1-[1,2-dihydro-1'-[(1-methyl-1H-benzimidazol-2-yl)methyl]spiro[3H-indole-3,4'-piperidin]-1-yl]- (CA INDEX NAME)

/ Structure 27 in file .gra /

RN 1004615-29-5 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1,2-dihydro-5,7-dimethyl-1'-[(1-methyl-1H-benzimidazol-2-yl)methyl]-1-(3-methylbutyl)- (CA INDEX NAME)

/ Structure 28 in file .gra /

RN 1004615-32-0 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1,2-dihydro-5-methyl-1'-[(1-methyl-1H-benzimidazol-2-yl)methyl]-1-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)

/ Structure 29 in file .gra /

RN 1004615-56-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1,2-dihydro-5,7-dimethyl-1'-[(1-methyl-1H-benzimidazol-2-yl)methyl]-1-(2-methylbutyl)- (CA INDEX NAME)

/ Structure 30 in file .gra /

TT ***1004619-35-5P***
PI, RCT (Reactant), SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of benzimidazolyl compds. as potentiators of mGluR2 or glutamate receptor useful in treatment and prevention of diseases)
RN 1004619-35-5 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid, 5-bromo-1,2-dihydro-1-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)

/ Structure 31 in file .gra /

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
CI

/ Structure 32 in file .gra /

AB Title compds. [I; R1 = (substituted) aliphatyl, amino; R2 = (substituted) cycloaliphatyl, heterocycloaliphatyl; L = bond, CH2, CH2CH2; n = 0, 1] were prepd. Thus, Et 4-[1'-acetyl-2',3'-dihydro-1'H-spiro[piperidine-4,4'-quinoline]-1-yl]piperidine-1-carboxylate [prepn. from tert-Bu 3-oxo-2,3-dihydrospiro[indene-1,4'-piperidine]-1'-carboxylate and Et 4-oxopiperidine-1-carboxylate given] modulated M1 and M4 receptors with activity at <2 mu M.
AN 2007:998649 CAPLUS <<LOGINID::20111010>>
DN 147:322962
TI Preparation of spiro condensed piperidines as modulators of muscarinic receptors

IN Makings, Lewis R.; Garcia-Guzman Blanco, Miguel; Hurley, Dennis J.; Drutu, Ioana; Raffai, Gabriel; Bergeron, Daniele M.; Nakatani, Akiko; Termin, Andreas P.; Silina, Alina

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 86 pp.
    CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO	KIND	DATE	APPLICATION NO	DATE
PI	WO 2007100670	A1	20070907	WO 2007-US4745	20070222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	AU 2007221220	A1	20070907	AU 2007-221220	20070222
	CA 2642649	A1	20070907	CA 2007-2642649	20070222
	EP 1987034	A1	20081105	EP 2007-751501	20070222
	EP 1987034	B1	20110720		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009527569	T	20090730	JP 2008-556443	20070222
	AT 517106	T	20110815	AT 2007-751501	20070222
	MX 2008010754	A	20080829	MX 2008-10754	20080821
	ZA 2008007236	A	20090826	ZA 2008-7236	20080821
	IN 2008KN03676	A	20090220	IN 2008-KN3676	20080908
	NO 2008004007	A	20081007	NO 2008-4007	20080919
	KR 2008098070	A	20081106	KR 2008-7022941	20080919
	CN 101479266	A	20090708	CN 2007-80014513	20081022
	US 20090227614	A1	20090910	US 2009-224270	20090216
PRAI	US 2006-775501P	P	20060222		
	US 2006-775524P	P	20060222		
	WO 2007-US4745	W	20070222		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:322962

TI ***947724-98-3***
    PL: PCT (Reactant); RACT (Reactant or reagent)
    (preprn. of spiro condensed piperidines as modulators of muscarinic receptors)

RN 947724-98-3 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1(2H)-carboxamide, N,N-dimethyl-1'-(4-piperidinyl)- (CA INDEX NAME)

/ Structure 33 in file .gra /

TI ***947724-94-9***
    PL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
    (preprn. of spiro condensed piperidines as modulators of muscarinic receptors)

RN 947724-94-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[1-[(dimethylamino)carbonyl]-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)

/ Structure 34 in file .gra /

OSC G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN
GI

/ Structure 35 in file .gra /

AB Title compds. [I; R1 = H, alkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocyclyl, etc.; R1R2, R1R3 = atoms to form heterocyclyl, heteroaryl; R2 = SO2R8; R3 = H, alkyl, Ac, (substituted) aralkyl; R4 = halo, alkyl, alkoxy, cyano, amino, Ac, CF3, OCF3, OCH2CF3; R8 = (substituted) cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, alkyl, alkenyl, alkynyl; X = CHCO2R9, CHCOR9, NSO2R9, CO, CHR9, NR9, etc.; Y = (CH2)n, O, CO, NCH3; A = alkyl; Z = atoms to form an aryl, heteroaryl ring; R9 = H, (substituted) alkyl, aralkyl, cycloalkylalkyl, heterocyclylalkyl, heteroarylalkyl; m = 0-6; n = 0-2] were prepd. Thus, title compd. (II) (soln. phase prepn. outlined) s.c. in mice substantially reduced cumulative food intake over a 4 h test.
AN 2005:451193 CAPLUS <<LOGINID::20111010>>
DN 142:482318
TI Preparation of spiroindolepiperidine amino acid amides as modulators of the growth hormone secretagogue receptor (GHS-R)
IN Distefano, Peter; Napper, Andrew; Navia, Manuel A.; Curtis, Rory A.; Luly, Jay; Pong, Jean-Francois; Thomas, Russell J.; Saunders, Jeffrey O.
PA Elixir Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1

PATENT NO	KIND	DATE	APPLICATION NO	DATE
PI WO 2005046682	A1	20050526	WO 2004-US36870	20041104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2544602	A1	20050526	CA 2004-2544602	20041104
US 20050187237	A1	20050825	US 2004-982997	20041104
US 7504506	B2	20090317		
EP 1682136	A1	20060726	EP 2004-800764	20041104

```
          B,  AT,  BE,  CH,  DE,  DK,  ES,  FR,  GB,  GR,  IT,  LI,  LU,  NL, SE, MC, PT,
          IE,  SI,  FI,  RO,  CY,  TR,  BG,  CZ,  EE,  HU,  PL,  SK,  TR
     CN 1901908              A      20070124    CN 2004-80039713          20041104
     TD 2007510662           T      20070426    TD 2006-538496            20041104
     IN 2006DN02346          A      20070803    IN 2006-DN2346            20060427
     MX 2006005038           A      20071212    MX 2006-5038              20060504
     US 2009264410           A1     20091022    US 2009-367585            20090209
     US 7897765              B2     20110301
PRAI US 2003-517058P         P      20031104
     US 2004-982997          A1     20041104
     WO 2004-US36870         W      20041104
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   CASREACT 142:482318; MARPAT 142:482318
TT     ***950835-73-1P***
     PL, PAC (Pharmacological activity), SPN (Synthetic preparation), THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preprn. of spiroindolepiperidine amino acid amides as modulators of
        growth hormone secretagogue receptor)
RN   950835-73-1  CAPLUS
CN   Carbamic acid, N-[(1R)-2-[1,2-dihydro-1-(2-methoxyacetyl)spiro[3H-indole-
     3,4'-piperidin]-1'-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-,
     1,1-dimethylethyl ester  (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 36 in file .gra /

OSC G   3     THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY     SESSION
FULL ESTIMATED COST                                     1.02      262.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY     SESSION
CA SUBSCRIBER PRICE                                     0.00       -6.96
```

FILE 'REGISTRY' ENTERED AT 14:28:36 ON 10 OCT 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 9 OCT 2011 HIGHEST RN 1334702-53-2
DICTIONARY FILE UPDATES: 9 OCT 2011 HIGHEST RN 1334702-53-2

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Users\rdesai\Documents\STN Express 8.4\Queries\10581175.str

L9 STRUCTURE UPLOADED

=> d l9
L9 HAS NO ANSWERS
L9 STR
/ Structure 37 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l9 ful
FULL SEARCH INITIATED 14:29:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 13163 TO ITERATE

100.0% PROCESSED 13163 ITERATIONS 4570 ANSWERS
SEARCH TIME: 00.00.01

L10 4570 SEA SSS FUL L9

FILE COVERS 1907 - 10 Oct 2011 VOL 155 ISS 16
FILE LAST UPDATED: 9 Oct 2011 (20111009/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2011

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2011.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10
L11 108 L10

=> s l11 and py<2003
23002483 PY<2003
L12 44 L11 AND PY<2003

=> d abs hib hitstr 4044
44 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):40-44

L12 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2011 ACS on STN
CI

/ Structure 38 in file .gra /

AB o-Phenylacetonitriles were converted to spiro compds. I [R = H, alkyl, cyano, alkanoyl, CO2Ph, phenylalkyl, phenylalkanoyl, alkenyl, cycloalkylalkyl, omega-benzoylalkyl (or its ethylene ketal); R1 = H, alkyl; R2 and R3 (same or different) are H, halo, CF3, alkyl, alkoxy, OH, NO2, NH2, NHCHO, NHAc; R4 = H, halo, alkyl, alkoxy, OH] in a series of reactions. I exhibited antidepressant and anticonvulsant activity and they are useful as tranquilizers (no data). The cycloalkylation of 2-FC6H4CH2CN by (ClCH2CH2)2NMe gave 4-cyano-4-(2-fluorophenyl)-1-methylpiperidine, the product was heated with LiAlH4 to give 1'-methylspiro[indoline-3,4'-piperidine], and the latter was N-arylated by 4-FC6H4CF3 to I (R = Me, R3 = 4-CF3, R1 = R2 = R4 = H).

AN 1980:604474 CAPLUS <<LOGINID::20111010>>
DN 93:204474
OREF 93:32621a,32624a
TI Spiro(indoline-3,4'-piperidine)s
IN Ong, Helen H.; Profitt, James A.
PA American Hoechst Corp., USA
SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 789,723, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4209625	A	19800624	US 1978-936185	19780823 <--
	DE 2816380	A1	19781207	DE 1978-2816380	19780415 <--
	FI 7801208	A	19781022	FI 1978-1208	19780419 <--
	DK 7801736	A	19781022	DK 1978-1736	19780420 <--
	NL 7804246	A	19781024	NL 1978-4246	19780420 <--

```
     ZA 7802273            A     19790425    ZA 1978-2273          19780420 <--
     AU 7835286            A     19791025    AU 1978-35286         19780420 <--
     AU 523799             B2    19820819
     CA 1105025            A1    19810714    CA 1978-301527        19780420 <--
     CH 7804590            A     19781022    CH 1978-4590          19780421 <--
     BE 866254             A1    19781023    BE 1978-187012        19780421 <--
     FR 2387981            A1    19781117    FR 1978-11909         19780421 <--
     FR 2387981            B1    19800829
     GB 1603030            A     19811118    GB 1978-15863         19780421 <--
     US 4307235            A     19811222    US 1980-121824        19800215 <--
     US 4345081            A     19820817    US 1980-198233        19801017 <--
     US 4379932            A     19830412    US 1981-332174        19811218 <--
     US 4379933            A     19830412    US 1981-332175        19811218 <--
     US 4408050            A     19831004    US 1981-332178        19811218 <--
     US 4477667            A     19841016    US 1981-332251        19811218 <--
PRAI US 1977-789723        A2    19770421
     US 1978-936185        A2    19780823
     US 1980-121824        A1    19800215
OS   CASREACT 93:204474, MARPAT 93:204474
TT      ***75391-64-9D***          ***75391-65-0D***
     BIOL (Biological study); PREP (Preparation)
        (prepn. of)
RN   75391-64-9  CAPLUS
CN   Spiro[3H-indole-3,4'-piperidine], 1-ethyl-1,2-dihydro-1'-methyl-  (CA
     INDEX NAME)

/ Structure 39 in file .gra /

RN   75391-65-0  CAPLUS
CN   Spiro[3H-indole-3,4'-piperidine], 1-ethyl-1,2-dihydro-1'-methyl-,
     hydrobromide (1:2)  (CA INDEX NAME)

/ Structure 40 in file .gra /

OSC.G   7     THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L12  ANSWER 41 OF 44  CAPLUS  COPYRIGHT 2011 ACS on STN
GI



/ Structure 41 in file .gra /

AB   Spiroindolinepiperidines I (R = substituted phenylalkyl, phenoxyalkyl,
     benzoylalkyl, phenylalkenyl, phenyl(hydroxy)alkyl, benzodioxanyl,
     naphthyloxymethyl; R1 = H, C1-4 alkyl; Ph, optionally substituted by
     halogen, C1-4 alkyl, alkoxy; R2 = H; R1R2 = C1-4 alkylene; X = O, H2) were
     prepd. for use as antihypertensives and central nervous system depressants
     (no data). Thus, N-methyloxindole was treated with (ClCH2CH2)2NCH2Ph to
     give I (R = CH2Ph, R1 = Me, R2 = H, X = O), which was debenzylated and
     treated with 4-chloro-1-(4-fluorophenyl)-1-ethylenedioxybutane to give I
     [R = 4-FC6H4CO(CH2)3, R1 = Me, R2 = H, X = O].
AN   1979:121443  CAPLUS <<LOGINID::20111010>>
DN   90:121443
ORPF 90:19223a,19226a
TI   Spiranic amine derivatives
PA   Sumitomo Chemical Co., Ltd., Japan
SO   Belg., 22 pp.
```

CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

	PATENT NO	KIND	DATE	APPLICATION NO	DATE	
PI	BE 867517	A1	19780918	BE 1978-188062	19780526	<--
	JP 54109983	A	19790829	JP 1978-15778	19780213	<--
	AU 7836169	A	19791122	AU 1978-36169	19780516	<--
	AU 511735	B2	19800904			
	DE 2822227	A1	19790816	DE 1978-2822227	19780522	<--
	ES 470155	A1	19790101	ES 1978-470155	19780524	<--
	SE 7805949	A	19790814	SE 1978-5949	19780524	<--
	CH 635841	A5	19830429	CH 1978-5662	19780524	<--
	FR 2442845	A1	19800627	FR 1978-15606	19780525	<--
	FR 2442845	B1	19810724			
	NL 7805814	A	19790815	NL 1978-5814	19780529	<--
	AT 7803888	A	19790915	AT 1978-3888	19780529	<--
	AT 356108	B	19800410			
	CA 1092106	A1	19801223	CA 1978-304287	19780529	<--
	US 4233307	A	19801111	US 1978-910537	19780530	<--

PRAI JP 1978-15778 A 19780213
OS MARPAT 90:121443
TI ***67677-69-4P*** ***67677-70-7P*** ***69214-85-3P***
69214-89-7P
(prepn. of)
BI. SPN (Synthetic preparation); PREP (Preparation)

RN 67677-69-4 CAPLUS
CN 1-Butanone, 4-(1,2-dihydro-1-methylspiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(4-fluorophenyl)- (CA INDEX NAME)

/ Structure 42 in file .gra /

RN 67677-70-7 CAPLUS
CN 1-Butanone, 4-(1-ethyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(4-fluorophenyl)-, hydrochloride (1:2) (CA INDEX NAME)

/ Structure 43 in file .gra /

RN 69214-85-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1(2H)-ethanol, 1,2-dihydro-1-methyl-1'-(2-phenylethyl)-, hydrochloride (1:2) (CA INDEX NAME)

/ Structure 44 in file .gra /

RN 69214-89-7 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-ethanol, 1-ethyl-1,2-dihydro-.alpha.-(1-naphthalenylmethyl)- (CA INDEX NAME)

/ Structure 45 in file .gra /

OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

L12 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2011 ACS on STN
GI

/ Structure 46 in file .gra /

AB Twenty-nine title derivs. I [R, R1, R2 = H, halo, alkyl, alkoxy, PhCH2O, HO; R3 = H, alkyl, (un)substituted Ph; R4 = H; or R3R4 = alkylene; Z = O, CO, CHOH, CH:CH, a single bond; Z1 = alkylene; Z2 = H2, O] and their HCl salts were prepd., e.g., by reaction of RR1R2C6H2ZZ1X (X = halo) with II. I had autonomic nerve-inhibitory, central nerve-inhibitory, analgesic, antiarrhythmic, and antihypertensive activities (no data). Thus, a mixt. of 1.63 g PhOCH2CH2Cl, 1.5 g II (R3 = Me, R4 = H, Z2O), 1.44 g K2CO3, and traces of KI was allowed to react 5 h at 90-100 degree, to give, after treatment with HCl, I HCl salt (R = R1 = R2 = R4 = H, R3 = Me, Z = Z2 = O, Z1 = CH2CH2)

AN 1978:529425 CAPLUS <<LOGINID::20111010>>

DN 89:129425

ODER 89:20025a,20028a

TI Spiroamine derivatives

IN Ono, Keiichi; Sagajima, Kikuo; Katsube, Junki; Yamamoto, Hisao

PA Sumitomo Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53068784	A	19780619	JP 1976-144149	19761130 <--
GB 1575800	A	19801001	GB 1978-19959	19780516 <--
PRAI JP 1976-144149	A	19761130		

*** 67677-63-8P *** *** 67677-69-4P *** *** 67677-70-7P ***
PI: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 67677-63-8 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine], 1,2-dihydro-1-methyl-1'-(2-phenylethyl)-, hydrochloride (1:1) (CA INDEX NAME)

/ Structure 47 in file .gra /

RN 67677-69-4 CAPLUS

CN 1-Butanone, 4-(1,2-dihydro-1-methylspiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(4-fluorophenyl)- (CA INDEX NAME)

/ Structure 48 in file .gra /

RN 67677-70-7 CAPLUS

CN 1-Butanone, 4-(1-ethyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(4-fluorophenyl)-, hydrochloride (1:2) (CA INDEX NAME)

/ Structure 49 in file .gra /

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L12 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2011 ACS on STN

GI For diagram(s), see printed CA Issue.

AB Attempts to isolate 3,3-spirocyclic indolenines, such as I, thought to be intermediates in the cyclization of benzylidenetryptamines to tetrahydro-.beta.-carbolines are described. One such spiropyrrolidinoindolenine, prepd. by an alternative route from a spirocyclic oxindole deriv., was shown to undergo an extremely facile acid-catalyzed rearrangement to a tetrahydro-.beta.-carboline. In

contrast, two piperidinospiroindolenines did not rearrange to beta-carbolines even under very vigorous acidic treatment. The relevance of these reactions to a new theory of electrophilic substitution in 3-substituted indoles and the biogenesis of indole alkaloids is discussed. 30 references.

AN 1968:39406 CAPLUS <<LOGINID::20111010>>

DN 68:39406

OREF 68:7643a,7646a

TI Electrophilic substitution in indoles. II. Formation of 3,3-spirocyclic indole derivatives from tryptamines and their rearrangement to beta-carbolines

AU Jackson, Anthony Hugh; Smith, Allan Edward

CS Univ. Liverpool, Liverpool, UK

SO Tetrahedron (1968), 24(1), 403-13
CODEN: TETRAB; ISSN: 0040-4020

DT Journal

LA English

TT ***16979-90-1P*** ***16979-91-2P*** ***16979-92-3P***
16979-97-8P ***19326-24-0P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparn. of)

RN 16979-90-1 CAPLUS

CN Spiro[3H-indole-3,4'-piperidin]-2-ol, 1,2-dihydro-1,1'-dimethyl- (CA INDEX NAME)

/ Structure 50 in file .gra /

RN 16979-91-2 CAPLUS

CN Spiro[3H-indole-3,4'-piperidin]-2-ol, 1,2-dihydro-1,1'-dimethyl-, compd. with 2,4,6-trinitrophenol (1:2) (CA INDEX NAME)

CM 1

CRN 16979-90-1

CMF C14 H20 N2 O

/ Structure 51 in file .gra /

CM 2

CRN 88-89-1

CMF C6 H3 N3 O7

/ Structure 52 in file .gra /

RN 16979-92-3 CAPLUS

CN Spiro[3H-indole-3,4'-piperidin]-2-ol, 1,2-dihydro-1,1'-dimethyl-, compd. with 2,4,6-trinitrophenol (1:1) (CA INDEX NAME)

CM 1

CRN 16979-90-1

CMF C14 H20 N2 O

/ Structure 53 in file .gra /

CM 2

CRN 88-89-1
CMF C6 H3 N3 O7

/ Structure 54 in file .gra /

RN 16979-97-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidin]-2-ol, 1,2-dihydro-5-methoxy-1,1'-dimethyl- (CA INDEX NAME)

/ Structure 55 in file .gra /

RN 19326-24-0 CAPLUS
CN Spiro[3H-indole-3,4'-piperidin]-2-ol, 1,2-dihydro-5-methoxy-1,1'-dimethyl-, hydrochloride (1:?) (CA INDEX NAME)

/ Structure 56 in file .gra /

OSC.G 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

L12 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2011 ACS on STN
GI For diagram(s), see printed CA Issue
AB Compds. of the general structure (I) are prepared. The compd. (II)(I, R = MeNHCO2, R' = R'' = H) has only 0.01-0.001 the cholinesterase-inhibiting potency of physostigmine; other I derivs. are completely inactive. Addn. of 29.7 g. NaNH2 to 68 g. 1-methyl-5-ethoxyoxindole and 61 g. MeN(CH2CH2Cl)2 (III) in 350 ml. PhMe at 35-45 degree., refluxing, addn. of 10 ml. EtOH after cooling, extn. with water, and with 2 N HCl, addn. of NH4OH to the HCl extn., dild. to 2 l., ether extn., evapn. of the ether, and taking the residue in petr. ether gives 46.5 g. 5-ethoxy-1,1'-dimethylspiro[piperidine-4,3'-ethoxyindole] (IV), m. 82-3 degree. LiAlH4 (19.4 g.) in 100 ml. ether added to 19.4 g. IV in 400 ml. tetrahydrofuran under N gives the compd. (V) (I, R = OEt, R' = R'' = H), mono-HCl salt, m. 233-5 degree., di-HCl salt, m. 231-3 degree.. IV in xylene refluxed with P2S5 and K2S2 and extd. with CHCl3 gives 5-ethoxy-1,1'-dimethylspiro[piperidine-4,3-thiooxindole], m. 133-7 degree., which gives V on electrolytic reduction in AcOH and 50% H2SO4 and purification by chromatographing on Al2O3. Heating 6 g. V 2HCl, and 50 g. pyridine-HCl to 180-90 degree., adding water and NH4OH, and extg. with CHCl3 gives the compd. (VI) (I, R = OH, R' = R'' = H), m. 192-8 degree. (from Me2CO), very unstable to air. VI (2.3 g.) treated dropwise with cooling with 3 drops NEt3 and 7 ml. MeNCO, the mixt. extd. with C6H6, the ext. washed with NaOH and water, and the C6H6 evapd. gives 700 mg. II, m. 140-1 degree. (from C6H6-petr. ether). From m-EtOC6H4NHMe, b15 138-40 degree. (N-Bz deriv., m. 109-10 degree.), is prepd. N-methyl-N-chloroacetyl-m-phenetidine, m. 73-4 degree., which gives 1-methyl-6-hydroxyoxindole, m. 209-10.degree.. 1-Methyl-6-ethoxyoxindole, m. 72-3 degree., III, and NaNH2 give 6'-ethoxy-1,1'-dimethylspiro[piperidine-4,3'-oxindole], m. 125-6.degree.; the corresponding thiooxindole m. 133-4 degree., is reduced electrolytically to I (R = R'' = H, R' = OEt), m. 68-9 degree. (from pentane). Refluxing 71.6 g. o-phenacetin with 9.2 g. powd. Na in 200 ml. C6H6, decanting from the excess Na, warming the soln. with 32 g. Me2SO4, washing with water and dil. HCl, evapg. the C6H6 in vacuo, taking the residue in 200 ml. alc., and 20 ml. water contg. 56 g. NaOH, heating 48 hrs., evapg. the alc., adding water, extg. with ether, extg. the ether with 2 N HCl, adding NH3, and again extg. with ether gives 20.6 g. N-methyl-o-phenetidine, b15 124-30.degree.; N-(p-nitrobenzoyl) deriv., m.

152-3 degree, N-Methyl- alpha -chloro-o-acetophenetidide, m. 42-3 degree, (6.84 g.), and 6.84 g. AlCl3 heated to 150 degree, then to 190 degree with an addnl. 6.84 g. AlCl3 dil. HCl added, and the mixt. extd. with CHCl3 gives on NaOH extn. 1 g. 1-methyl-7-hydroxyindole, m. 227-8 degree, (from C6H12), and from the CHCl3 soln. 1.6 g. 1-methyl-2(3H)-benzoxazolone, m. 56-7 degree, (from petr. ether). LiAlH4 reduction of 1,1'-dimethylspiro[piperidine-4,3'-oxindole] gives I(R = R' = R'' = H), m. 49-50.degree. (HCl salt, m. 243-5.degree.; salicylate, m. 101-2 degree.)

AN 1952:57258 CAPLUS <<LOGINID::20111010>>
DN 46:57258
OREF 46:9571d-i,9572a-b
TI The synthesis of physostigmine-like compound
AU Kretz, F.; Muller, J. M.; Schlittler, E.
CS Univ. Basel, Switz.
SO Helvetica Chimica Acta (***1952***), 35, 520-8
CODEN: HCACAV; ISSN: 0018-019X
DT Journal
LA German
TI ***860420-54-8*** Spiro[indoline-3,4'-piperidine], 5-ethoxy-1,1'-dimethyl- (and hydrochlorides)
RN 860420-54-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 5-ethoxy-1,2-dihydro-1,1'-dimethyl- (CA INDEX NAME)

/ Structure 57 in file .gra /

TI ***845825-82-3*** , Spiro[indoline-3,4'-piperidine], 1,1'-dimethyl- (and salts)
RN 845825-82-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1,2-dihydro-1,1'-dimethyl- (CA INDEX NAME)

/ Structure 58 in file .gra /

TI ***845825-83-4P*** Salicylic acid, compds. with 1,1'-dimethylspiro[indoline-3,4'-piperidine] ***860420-41-3P*** , Spiro[indoline-3,4'-piperidin]-5-ol, 1,1'-dimethyl-, methylcarbamate, (ester) ***860420-44-6P*** Spiro[indoline-3,4'-piperidin]-5-ol, 1,1'-dimethyl- ***860420-51-5P*** , Spiro[indoline-3,4'-piperidine], 6-ethoxy-1,1'-dimethyl-
RL: PREP (Preparation)
(prepn. of)
RN 845825-83-4 CAPLUS
CN Benzoic acid, 2-hydroxy-, compd. with 1,2-dihydro-1,1'-dimethylspiro[3H-indole-3,4'-piperidine] (1:1) (CA INDEX NAME)

CM 1

CRN 845825-82-3
CMF C14 H20 N2

/ Structure 59 in file .gra /

CM 2

CRN 69-72-7
CMF C7 H6 O3

/ Structure 60 in file .gra /

RN 860420-41-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidin]-5-ol, 1,2-dihydro-1,1'-dimethyl-,
5-(N-methylcarbamate) (CA INDEX NAME)

/ Structure 61 in file .gra /

RN 860420-44-6 CAPLUS
CN Spiro[3H-indole-3,4'-piperidin]-5-ol, 1,2-dihydro-1,1'-dimethyl- (CA
INDEX NAME)

/ Structure 62 in file .gra /

RN 860420-51-5 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 6-ethoxy-1,2-dihydro-1,1'-dimethyl- (CA
INDEX NAME)

/ Structure 63 in file .gra /

Connecting via Winsock to STN at pto-stn on port 23

Welcome to STN International! Enter x:X
LOGINID:SSSPTA1612RXD
PASSWORD:
THIS LOGINID IS CURRENTLY IN USE
DO YOU WISH TO RESUME THE PREVIOUS SESSION? Y/(N)/?:Y
THE PREVIOUS SESSION IS BEING DISCONNECTED.
PLEASE LOG IN AGAIN TO BE RECONNECTED
SYSTEM LOGOFF AT 15:10:54 ON 10 OCT 2011 US EASTERN TIME

Connection closed by remote host

A new logon attempt will be made when this window closes. If
you chose to RESUME PREVIOUS SESSION, then continue with the
logon process as normal. If not, choose Cancel or <ESC> to
interrupt the logon process.

y
Connecting via Winsock to STN at pto-stn on port 23

```
Welcome to STN International!  Enter x:X
LOGINID:SSSPTA1612RXD
PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 15:11:18 ON 10 OCT 2011
FILE 'STNGUIDE' ENTERED AT 15:11:18 ON 10 OCT 2011
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS                        SINCE FILE       TOTAL
                                              ENTRY     SESSION
FULL ESTIMATED COST                            5.36      498.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE       TOTAL
                                              ENTRY     SESSION
CA SUBSCRIBER PRICE                            0.00      -11.31
53-2
CAS Information Use Policies apply and are available at:
http://www.cas.org/legal/infopolicy.html
TSCA INFORMATION NOW CURRENT THROUGH June 24, 2011.
  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.
REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
http://www.cas.org/support/stngen/stndoc/properties.html
=>
Uploading C:\Users\rdesai\Documents\STN Express 8.4\Queries\10581175.str
L13     STRUCTURE UPLOADED
=> d l13
L13 HAS NO ANSWERS
L13                 STD
/ Structure 64 in file .gra /

Structure attributes must be viewed using STN Express query preparation.

=> s l13
SAMPLE SEARCH INITIATED 15:11:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      475 TO ITERATE
100.0% PROCESSED      475 ITERATIONS                          48 ANSWERS
SEARCH TIME: 00.00.01
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          8193 TO    10807
PROJECTED ANSWERS:              545 TO     1375
```

L14 48 SEA SSS SAM L13

-~ s l13 ful

FULL SEARCH INITIATED 15:12:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 9929 TO ITERATE

100.0% PROCESSED 9929 ITERATIONS 1070 ANSWERS

SEARCH TIME: 00.00.01

L15 1070 SEA SSS FUL L13

-> file caplus

C

FILE COVERS 1907 - 10 Oct 2011 VOL 155 ISS 16

FILE LAST UPDATED: 9 Oct 2011 (20111009/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2011

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2011.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

-~ s l15

L16 53 L15

-~ d abs bib hitstr 45-53

L16 ANSWER 45 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN

CI

/ Structure 65 in file .gra /

AB Piperidinopropylpiperidine derivs. were prepd. for use as human NK3 receptor antagonists (no data). Thus, 3,4-Cl2C6H3CH2CN was treated with CH2:CHCO2Me to give 3,4-Cl2C6H3CH(CN)(CH2CH2CO2Me)2 which was cyclized to the piperidonepropanoate and reduced to 3-(3,4-dichlorophenyl)-3-(3-hydroxypropyl)piperidine (I). I was N-benzoylated, converted to the mesylate, and aminated to give the piperidinopropylpiperidine II.

AN 1997:302959 CAPLUS <<LOGINID::20111010>>

DN 126:277403

OREF 126:53775a,53778a

TI Novel human NK3 receptor-selective antagonist compounds containing them

IN Bichon, Daniel; Edmonds-Alt, Xavier; Gueule, Patrick; Proietto, Vincenzo; Van Broeck, Didier

PA Sanofi, Fr.

SO PCT Int. Appl., 189 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PT WO 9710211 A1 19970320 WO 1996-FR1416 19960913
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG
FR 2738819 A1 19970321 FR 1995-10776 19950914
FR 2738819 B1 19971205
CA 2232007 A1 19970320 CA 1996-2232007 19960913
CA 2593316 A1 19970320 CA 1996-2593316 19960913
AU 9669825 A 19970401 AU 1996-69825 19960913
BR 9610081 A 19990105 BR 1996-10081 19960913
JP 11514983 T 19991221 JP 1997-511718 19960913
EP 1019373 A1 20000719 EP 1996-931126 19960913
EP 1019373 B1 20031112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
EP 1241168 A1 20020918 EP 2002-10824 19960913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
AT 254104 T 20031115 AT 1996-931126 19960913
US 6028082 A 20000222 US 1998-43247 19980312
US 6291672 B1 20010918 US 1998-437203 19981109
US 2002004232A A1 20020425 US 2001-954862 20010918
US 6710042 B2 20040323
US 2004220223 A1 20041104 US 2004-805733 20040322
JP 2008115182 A 20080522 JP 2007-296689 20071115
PRAI FR 1995-10776 A 19950914
CA 1996-2232007 A3 19960913
EP 1996-931126 A3 19960913
JP 1997-511718 A3 19960913
WO 1996-FR1416 W 19960913
US 1998-43247 A3 19980312
US 1998-437203 A3 19981109
US 2001-954862 A3 20010918
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 126:277403
TI ***188979-65-9***
RL: PAC (Reactant); RACT (Reactant or reagent)
(preps. of piperidinopropylpiperidines as NK3 antagonists)
RN 188979-65-9 CAPLUS
CN Ethanone, 1-(1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1-yl)-, hydrochloride (1:1) (CA INDEX NAME)

/ Structure 66 in file .gra /

TI ***188979-64-8P***
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preps. of piperidinopropylpiperidines as NK3 antagonists)
RN 188979-64-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1-acetyl-1'-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-1,2-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

/ Structure 67 in file .gra /

OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

RE CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 46 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN
AB A method for solid phase synthesis of spiroindolines using the Fischer indole reaction is describe. Various arylhydrazines react cleanly with polymer bound piperidine-4-carbovaldehyde in TFA/CH2Cl2. The products are isolated in good yields and high purity.
AN 1997:168875 CAPLUS <<LOGINID::20111010>>
DN 126:277373
ODER 126:53771a,53774a
TI Solid phase synthesis of spiroindoline
AU Cheng, Yuan; Chapman, Kevin T.
CS Dep. Mol. Design Diversity, Merck Res. Lab., Rahway, NJ, 07065, USA
SO Tetrahedron Letters (1997), 38(9), 1497-1500
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 126:277373
TE ***188646-86-8P*** ***188646-87-9P*** ***188646-88-0P***
188646-89-1P ***188646-90-4P*** ***188646-91-5P***
188646-92-6P ***188646-93-7P*** ***188646-94-8P***
188646-95-9P ***188646-96-0P*** ***188646-97-1P***
188646-98-2P ***188646-99-3P*** ***188647-00-9P***
188647-02-1P ***188647-03-2P***
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid phase synthesis of spiroindolines)
RN 188646-86-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 68 in file .gra /

RN 188646-87-9 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-7-bromo-1,2-dihydro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 69 in file .gra /

RN 188646-88-0 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-.gamma.-oxo-5-(trifluoromethyl)-, methyl ester (CA INDEX NAME)

/ Structure 70 in file .gra /

RN 188646-89-1 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-4,6-dichloro-1,2-dihydro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 71 in file .gra /

RN 188646-90-4 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-6-nitro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 72 in file .gra /

RN 188646-91-5 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-5-nitro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 73 in file .gra /

RN 188646-92-6 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-5,6-dichloro-1,2-dihydro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 74 in file .gra /

RN 188646-93-7 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-5,7-dichloro-1,2-dihydro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 75 in file .gra /

RN 188646-94-8 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-.gamma.-oxo-4,6-bis(trifluoromethyl)-, methyl ester (CA INDEX NAME)

/ Structure 76 in file .gra /

RN 188646-95-9 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-5-(1,1-dimethylethyl)-1,2-dihydro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 77 in file .gra /

RN 188646-96-0 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-.gamma.-oxo-5-(phenylmethoxy)-, methyl ester (CA INDEX NAME)

/ Structure 78 in file .gra /

RN 188646-97-1 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-4,7-dimethyl-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 79 in file .gra /

RN 188646-98-2 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-5-methoxy-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 80 in file .gra /

RN 188646-99-3 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-.gamma.-oxo-5-(trifluoromethoxy)-, methyl ester (CA INDEX NAME)

/ Structure 81 in file .gra /

RN 188647-00-9 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-5-(2-oxazolyl)-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 82 in file .gra /

RN 188647-02-1 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-1,2-dihydro-4-nitro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 83 in file .gra /

RN 188647-03-2 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanoic acid, 1-acetyl-4,5-dichloro-1,2-dihydro-.gamma.-oxo-, methyl ester (CA INDEX NAME)

/ Structure 84 in file .gra /

OSC.G 41 THERE ARE 41 CAPLUS RECORDS THAT CITE THIS RECORD (41 CITINGS)
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 47 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed certain novel compds. identified as spiro piperidines and homologs I and II wherein, R1 = e.g., C1-10 alkyl, aryl, aryl-(C1-6 alkyl), R2 = e.g., H, C1-6 alkyl, C3-7 cycloalkyl, R3a and R3b are independently, e.g., H, halo, C1-6 alkyl, R4 and R5 are independently, H, C1-6 alkyl, substituted C1-6 alkyl where the substituents on alkyl are, e.g., 1 to 5 halo, 1 to 3 hydroxy, R6 is H or C1-6 alkyl, A is (CH2)xCR7R7a(CH2)y or Z(CH2)xCR7R7a(CH2)y wherein x and y are independently 0, 1, 2, or 3, Z is NR2 or O, R7 and R7a are independently, e.g., H, C1-6 alkyl, OR2, B, D, E, and F are independently selected from CR8R10, O, CO, SOm, NR9, wherein one or two of B, D, E, or F may be optionally absent to provide a 5, 6, or 7-membered ring, R8 and R10 are independently, e.g., H, R2, OR2, R9 = e.g., R2, COR2, SO2R2, m is 0, 1, or 2, n is 1 or 2, G, H, I and J are carbon, nitrogen, sulfur or oxygen atoms, such that one or two is a heteroatom, and where one of G, H, I or J may be optionally absent to afford a 5 or 6 membered heterocyclic arom. ring; and the pharmaceutically acceptable salts and individual

diastereomers thereof, which promote the release of growth hormone in humans and animals (no data). This property can be utilized to promote the growth of food animals to render the prodn. of edible meat products more efficient, and in humans, to treat physiol. or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compns. contg. such spiro compds. as the active ingredient thereof are also disclosed. Thus, e.g., 1'-[(t-butyloxycarbonyl)spiro[1H-indene-1,4'-piperidine] was subjected to hydroboration/oxidn., to provide 1'-(t-butyloxycarbonyl)-2,3-dihydro-3-oxospiro[1H-indene-1,4'-piperidine], deprotection followed by trifluoroacetylation afforded the trifluoroacetamide. Schmidt reaction of the latter provided 3,4-dihydro-2-oxospiro[piperidine-4,4'(1H)-quinoline] trifluoroacetamide (together with its spiroisoquinoline isomer); sapon. followed by coupling with alpha-[[2-[[(1,1-dimethylethoxy)carbonyl]amino]-2,2-dimethyl-1-oxoethyl]amino]-1H-indole-3-propanoic acid (prepn. given) and deprotection provided N-[1(R)-[(3,4-dihydro-2-oxospiro[piperidine-4,4'(1H)-quinolin]-1'-yl)carbonyl]-2-(indol-3-yl)ethyl]-2-amino-2-methylpropanamide hydrochloride (III.HCl).

AN 1996:469925 CAPLUS <<LOGINID::20111010>>

DN 125:196372

OREF 125:36799a,36802a

TI Spiro piperidines which promote release of growth hormone

IN Chen, Meng-Hsin; Johnston, David B. R.; Nargund, Ravi P.; Patchett, Arthur A.; Tata, James R.; Yang, Lihu

PA Merck and Co., Inc., USA

SO U.S., 48 pp. Cont.-in-part of U.S. Ser. No. 989,322, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5536716	A	19960716	US 1993-147226	19931103
	WO 9413696	A1	19940623	WO 1993-US11038	19931115
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 9413367	A1	19940901	WO 1993-US11137	19931115
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	HU 72076	A2	19960328	HU 1995-1682	19931115
	HU 73228	A2	19960729	HU 1995-1681	19931115
	DE 176993	B1	19990831	DE 1993-309331	19931115
	DE 21685I2	C2	20011010	DE 1995-113349	19931115
	SK 282166	B6	20011106	SK 1995-759	19931115
	CA 2110670	A1	19940612	CA 1993-2110670	19931203
	CA 2110670	C	20010417		
	CA 2110672	A1	19940612	CA 1993-2110672	19931203
	EP 615977	A1	19940921	EP 1993-309867	19931208
	EP 615977	B1	20020703		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	AT 220071	T	20020715	AT 1993-309867	19931208
	DE 615977	E	20021031	DE 1993-309867	19931208
	ES 2177538	T3	20021216	ES 1993-309867	19931208
	AU 9352320	A	19940623	AU 1993-52320	19931210
	AU 673552	B2	19961114		
	AU 9352321	A	19940623	AU 1993-52321	19931210
	AU 673017	B2	19961024		

	ZA 9309272	A	19940808	ZA 1993-9272	19931210
	ZA 9309274	A	19940808	ZA 1993-9274	19931210
	TD 06263737	A	19940930	JP 1993-341522	19931210
	TD 2509530	B2	19960619		
	HU 9301486	B1	20030831	HU 1993-1486	19931210
	CN 1092071	A	19940914	CN 1993-112858	19931211
	CN 1034733	C	19970430		
	FI 9502862	A	19950609	FI 1995-2862	19950609
	FI 9502863	A	19950609	FI 1995-2863	19950609
	NO 9502294	A	19950810	NO 1995-2294	19950609
	NO 9502295	A	19950810	NO 1995-2295	19950609
	US 5652235	A	19970729	US 1996-641311	19960430
PRAI	US 1992-989322	B2	19921211		
	US 1993-146848		19931103		
	US 1993-147226	A	19931103		
	WO 1993-US11038	W	19931115		
	WO 1993-US11137	W	19931115		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 125:196372

TT ***159633-96-2P*** ***159634-43-2P***
BI. BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FFD (Food or feed use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(spiro piperidines which promote release of growth hormone)

RN 159633-96-2 CAPLUS

CN Propanamide, N-[2-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-amino-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 85 in file .gra /

RN 159634-43-2 CAPLUS

CN Propanamide, N-[(1R)-2-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-amino-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 86 in file .gra /

TT ***180466-15-3P***
BI. BCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(spiro piperidines which promote release of growth hormone)

RN 180466-15-3 CAPLUS

CN Carbamic acid, [2-[[2-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 87 in file .gra /

OSC.G 38 THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (60 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 48 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN

GI

/ Structure 88 in file .gra /

AB A general approach to spiro-piperidinyl heterocycles I (Z = S, O, NH, NAc) was obtained from the key intermediates II via an efficient radical reaction
AN 1996:457322 CAPLUS <<LOGINID::20111010>>
DN 125:221546
ODFF 125:41405a,41408a
TI Free radical method for the synthesis of spiro-piperidinyl heterocycles
AU Chen, Meng-Hsin; Abraham, John A.
CS Dep. Medicinal Chem., Merck Res. Lab., Rahway, NJ, 07065, USA
SO Tetrahedron Letters (1996), 37(30), 5233-5234
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier
DT Journal
LA English
OS CASREACT 125:221546
TI ***181271-51-2***
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of spiro-piperidinyl heterocycles)
RN 181271-51-2 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-carboxylic acid, 1-acetyl-1,2-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)

/ Structure 89 in file .gra /

OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

L16 ANSWER 49 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN
CI

/ Structure 90 in file .gra /

AB Spirocyclic nitrogen-heterocyclic compds. were disclosed as tachykinin receptor antagonists useful for the treatment of inflammatory diseases, pain or migraine, and asthma. In particular, said compds. were shown to be neurokinin antagonists. Many example compds. are claimed. One such specific compd. is N-[3-(3,4-dichlorophenyl)-4-[1,2-dihydro-1-(sulfonylmethyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]butyl]-2,2-dimethylpropanamide (I).
AN 1995:781772 CAPLUS <<LOGINID::20111010>>
DN 123:169671
ODFF 123:30303a,30306a
TI Preparation of spirocyclic compounds as neurokinin antagonists
IN MacCoss, Malcolm; Mills, Sander G.; Shah, Shrenik K.; Chiang, Yuan-Ching P.; Dunn, Patrick T.; Koyama, Hiroo; Finke, Paul E.; Qi, Hongbo; Robichaud, Albert J.
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 226 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PT WO 9429309 A1 19941222 WO 1994-US5545 19940517
W: AM, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TT, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
CA 2163995 A1 19941222 CA 1994-2163995 19940517
AU 9472011 A 19950103 AU 1994-72011 19940517
AU 680020 B2 19970717
EP 702681 A1 19960327 EP 1995-901979 19940517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
JP 08511522 T 19961203 JP 1994-501802 19940517
ZA 9403946 A 19950120 ZA 1994-3946 19940606
PRAI US 1993-72904 A 19930607
WO 1994-US5545 W 19940517
OS MARPAT 123:169671
TI ***167484-19-7D***
BI: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preprn. of spirocyclic compds. as kinin receptor antagonists)
RN 167484-19-7 CAPLUS
CN Ethanone, 1-(1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1-yl)- (CA INDEX NAME)

/ Structure 91 in file .gra /

TI ***167484-09-5D*** ***167484-10-8D*** ***167484-12-0D***
167484-17-5D ***167484-39-1D*** ***167484-48-2D***
167484-49-3D ***167484-50-6D*** ***167484-51-7D***
167484-55-1D ***167485-05-4D*** ***167485-08-7D***
167485-11-2D ***167485-12-3D*** ***167485-13-4D***
167485-14-5D ***167485-15-6D*** ***167485-16-7D***
167485-17-8D ***167485-18-9D*** ***167485-19-0D***
167485-20-3D ***167485-21-4D*** ***167485-22-5D***
167485-23-6D ***167485-24-7D*** ***167485-25-8D***
167485-26-9D ***167485-27-0D*** ***167485-28-1D***
167485-33-8D ***167485-34-9D*** ***167485-37-2D***
167485-41-8D ***167485-42-9D*** ***167485-43-0D***
167485-46-3D ***167485-47-4D*** ***167485-48-5D***
167485-50-9D ***167485-52-1D*** ***167485-55-4D***
167485-56-5D ***167485-57-6D*** ***167485-58-7D***
167485-59-8D ***167485-60-1D*** ***167485-80-5D***
167485-81-6D ***167485-82-7D*** ***167485-83-8D***
167485-84-9D ***167485-85-0D*** ***167485-90-7D***
BI: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preprn. of spirocyclic compds. as kinin receptor antagonists)
RN 167484-09-5 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N,3,5-trimethyl- (CA INDEX NAME)
Absolute stereochemistry.

/ Structure 92 in file .gra /

RN 167484-10-8 CAPLUS
CN Benzamide, N-[(2S)-2-(3,4-dichlorophenyl)-4-[1,2-dihydro-1-(1-oxopropyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]butyl]-N,3,5-trimethyl- (CA INDEX NAME)
Absolute stereochemistry.

/ Structure 93 in file .gra /

RN 167484-12-0 CAPLUS

CN Benzamide, N-[(2S)-2-(3,4-dichlorophenyl)-4-[1-(2,2-dimethyl-1-oxopropyl)-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl]butyl]-N,3,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 94 in file .gra /

RN 167484-17-5 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-3-fluoro-N-methyl-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 95 in file .gra /

RN 167484-39-1 CAPLUS

CN Benzamide, N-[(2S)-4-[1-(aminoacetyl)-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl]-2-(3,4-dichlorophenyl)butyl]-N,3,5-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 96 in file .gra /

RN 167484-48-2 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(4-fluorophenyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 97 in file .gra /

RN 167484-49-3 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3-chlorophenyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 98 in file .gra /

RN 167484-50-6 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(4-chlorophenyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 99 in file .gra /

RN 167484-51-7 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-difluorophenyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 100 in file .gra /

RN 167484-55-1 CAPLUS

CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(4-pyridinyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

/ Structure 101 in file .gra /

/ Structure 102 in file .gra /

RN 167485-05-4 CAPLUS

CN Carbamic acid, [(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 103 in file .gra /

RN 167485-08-7 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine, 1-acetyl-5-chloro-.beta.-(3,4-dichlorophenyl)-1,2-dihydro-N-methyl-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 104 in file .gra /

RN 167485-11-2 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine, 1-acetyl-.beta.-(3,4-dichlorophenyl)-1,2-dihydro-N,5-dimethyl-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 105 in file .gra /

RN 167485-12-3 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine, 1-acetyl-.beta.-(3,4-dichlorophenyl)-5-fluoro-1,2-dihydro-N-methyl-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 106 in file .gra /

RN 167485-13-4 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine, 1-acetyl-.beta.-(3,4-dichlorophenyl)-6-fluoro-1,2-dihydro-N-methyl-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 107 in file .gra /

RN 167485-14-5 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine,
1-acetyl-.beta.-(3,4-dichlorophenyl)-4-fluoro-1,2-dihydro-N-methyl-,
(.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 108 in file .gra /

RN 167485-15-6 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-4-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 109 in file .gra /

RN 167485-16-7 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-6-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 110 in file .gra /

RN 167485-17-8 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-4-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N,3,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 111 in file .gra /

RN 167485-18-9 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 112 in file .gra /

RN 167485-19-0 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-5-chloro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N,3,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 113 in file .gra /

RN 167485-20-3 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-3-chloro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 114 in file .gra /

RN 167485-21-4 CAPLUS
CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-

piperidinl-1'-yl)-2-(3,4-dichlorophenyl)butyl]-3,5-dichloro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 115 in file .gra /

RN 167485-22-5 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N,3-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 116 in file .gra /

RN 167485-23-6 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N,3,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 117 in file .gra /

RN 167485-24-7 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-3-(1-methylethoxy)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 118 in file .gra /

RN 167485-25-8 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-3,5-bis(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 119 in file .gra /

RN 167485-26-9 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydro-5-methylspiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N,3,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 120 in file .gra /

RN 167485-27-0 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 121 in file .gra /

/ Structure 122 in file .gra /

RN 167485-28-1 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 123 in file .gra /

RN 167485-33-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(2S)-4-(1-acetyl-6-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 124 in file .gra /

/ Structure 125 in file .gra /

RN 167485-34-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(2S)-4-(1-acetyl-4-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 126 in file .gra /

/ Structure 127 in file .gra /

RN 167485-37-2 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine, 1-acetyl-.beta.-(3,4-dichlorophenyl)-5-fluoro-N-[(4-fluoro-1-naphthalenyl)methyl]-1,2-dihydro-N-methyl-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 128 in file .gra /

/ Structure 129 in file .gra /

RN 167485-41-8 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 130 in file .gra /

RN 167485-42-9 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-3-chloro-4-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 131 in file .gra /

RN 167485-43-0 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N,3,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 132 in file .gra /

RN 167485-46-3 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N,3,5-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 133 in file .gra /

RN 167485-47-4 CAPLUS

CN Benzamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N-methyl-3-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 134 in file .gra /

RN 167485-48-5 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-4-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 135 in file .gra /

/ Structure 136 in file .gra /

RN 167485-50-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(2S)-4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 137 in file .gra /

RN 167485-52-1 CAPLUS
CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-phenylbutyl]-N,3,5-trimethyl- (CA INDEX NAME)

/ Structure 138 in file .gra /

RN 167485-55-4 CAPLUS
CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-methylbutyl]-N,3,5-trimethyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 139 in file .gra /

RN 167485-56-5 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine, 1-acetyl-.beta.-(3,4-dichlorophenyl)-N-(4-fluoro-1-naphthalenyl)-1,2-dihydro-N,.alpha.-dimethyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 140 in file .gra /

RN 167485-57-6 CAPLUS
CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-ethylbutyl]-N,3,5-trimethyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 141 in file .gra /

RN 167485-58-7 CAPLUS
CN Benzamide, N-[4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-ethylbutyl]-N,3,5-trimethyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 142 in file .gra /

RN 167485-59-8 CAPLUS
CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-propylbutyl]-N,3,5-trimethyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 143 in file .gra /

RN 167485-60-1 CAPLUS
CN Benzamide, N-[4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-propylbutyl]-N,3,5-trimethyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 144 in file .gra /

RN 167485-80-5 CAPLUS

CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-methylbutyl]-N,3,5-trimethyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 145 in file .gra /

RN 167485-81-6 CAPLUS

CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamine, 1-acetyl-.beta.-(3,4-dichlorophenyl)-N-(4-fluoro-1-naphthalenyl)-1,2-dihydro-N,.alpha.-dimethyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 146 in file .gra /

RN 167485-82-7 CAPLUS

CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-ethylbutyl]-N,3,5-trimethyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 147 in file .gra /

RN 167485-83-8 CAPLUS

CN Benzamide, N-[4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-ethylbutyl]-N,3,5-trimethyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 148 in file .gra /

RN 167485-84-9 CAPLUS

CN Benzamide, N-[4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-propylbutyl]-N,3,5-trimethyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 149 in file .gra /

RN 167485-85-0 CAPLUS

CN Benzamide, N-[4-(1-acetyl-5-fluoro-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)-1-propylbutyl]-N,3,5-trimethyl-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 150 in file .gra /

RN 167485-90-7 CAPLUS

CN Benzoic acid, 3,5-bis(trifluoromethyl)-, 4-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-2-(3,4-dichlorophenyl)butyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 151 in file .gra /

RSC (3 CITINGS) THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
RE CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 50 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN
AB Spiro-substituted azacycles (Markush included) are disclosed. The compds. of the invention are tachykinin receptor antagonists, esp. neurokinin-3 receptor antagonists, and are useful in the treatment of central nervous system disorders, inflammatory diseases, pain, migraine, asthma, and emesis. Synthesis of compds. of the invention, e.g. 1-[3-(S)-(3,4-dichlorophenyl)-4-(N-benzyl-N-methyl)amino-4-oxo-butyl]-4-(2-pyridyl)-piperazine, is included. Is are data on their ability to displace radioactive ligand from NK-1 receptors, NK-2 receptors, and NK-3 receptors.
AN 1995:759109 CAPLUS <<LOGINID::20111010>>
DN 123:218432
ODER 123:385993a,386023a
TI Spiro-substituted azacycles as neurokinin-3 antagonists, their preparation, and their use for treatment of central nervous system disorders and other disorders
IN Shah, Shrenik K.
PA Merck and Co., Inc., USA
SO U.S., 16 pp.
CODEN: USXXAM
DT Patent
LA English
FAN CNT 1

PATENT NO	KIND	DATE	APPLICATION NO	DATE
US 5434158	A	19950718	US 1994-233487	19940426
CA 2188031	A1	19951102	CA 1995-2188031	19950421
WO 9529931	A1	19951102	WO 1995-US4881	19950421
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, US, UZ,				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9523915	A	19951116	AU 1995-23915	19950421
EP 758238	A1	19970219	EP 1995-917091	19950421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09512272	T	19971209	JP 1995-527766	19950421
PRAI US 1994-233487	A	19940426		
WO 1995-US4881	W	19950421		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
RSC CASREACT 123:218432
TI ***168201-73-8D***
BI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(spiro-substituted azacycles as tachykinin receptor antagonists, their prepn. and their use for treatment of central nervous system disorders and other disorders)
RN 168201-73-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine]-1'-butanamide, 1-acetyl-.alpha.-(3,4-dichlorophenyl)-1,2-dihydro-N-methyl-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 152 in file .gra /

OSC.G 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)
RE CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 51 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN
AB A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone. L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, LH, thyroxine, and prolactin after oral administration of 1 mg/kg. Only modest increases in cortisol were obsd. Based on these properties, L-163,191 has been selected for clin. studies.
AN 1995:700762 CAPLUS <<LOGINID::20111010>>
DN 123:160569
OREF 123:28315a,28318a
TI Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue
AU Patchett, A. A.; Nargund, R. P.; Tata, J. R.; Chen, M.-H.; Barakat, K. J.; Johnston, D. B. R.; Cheng, K.; Chan, W. W.-S.; Butler, B.; et al.
CS Dep. Med. Chem., Merck Res. Lab., Rahway, NJ, 07065-0900, USA
SO Proceedings of the National Academy of Sciences of the United States of America (1995), 92(15), 7001-5
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
IT ***159634-43-2P***
PT, RAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), SPN (Synthetic preparation), THU (Therapeutic use); BIOL (Biological study), PREP (Preparation), USES (Uses)
(prepn. and biol. activities of analogs of the nonpeptidyl L-692-429 growth hormone secretagogue)
RN 159634-43-2 CAPLUS
CN Propanamide, N-[(1R)-2-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-amino-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 153 in file .gra /

OSC.G 259 THERE ARE 259 CAPLUS RECORDS THAT CITE THIS RECORD (260 CITINGS)

L16 ANSWER 52 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN
AB Bisphosphonates in combination with growth hormone secretagogues (Markush included for both bisphosphonates and growth hormone secretagogues) reduce the deleterious effects of osteoporosis in elderly patients. Prepn. of selected compds. of the invention is described. The effect of N-[1(R)-((1,2-dihydro-1-methanesulfonylspiro(3H-indole-3,4'-piperidin)-1'-yl)carbonyl)-3-phenylpropyl]-2-amino-2-methylpropanamide, alone and in combination with pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid), on bone in old female rats was evaluated. Results indicated that the growth hormone secretagogue restored bone formation that had been suppressed by the bisphosphonate to control levels. Addnl. the was no difference in osteoclast surface (bone resorption) as a result of treatment with the growth hormone secretagogue.
AN 1995:686929 CAPLUS <<LOGINID::20111010>>

RN 123.74929
ORPF 123.13067a 13070a
TI Combination of bisphosphonates and growth hormone secretagogues for treatment of osteoporosis, and their preparation
IN Gertz, Barry J.; Rodan, Gideon A.; Smith, Roy G.; Wyvratt, Matthew J.; Patchett, Arthur A
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511029	A1	19950427	WO 1994-US11912	19941018
	W: AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, EE, ES, FI, GB, GE, HU, JP, KG, KP, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2173333	A1	19950427	CA 1994-2173333	19941018
	AU 9480836	A	19950508	AU 1994-80836	19941018
	BR 9407869	A	19961029	BR 1994-7869	19941018
	CN 1136278	A	19961120	CN 1994-194311	19941018
	HU 75224	A2	19970428	HU 1996-1013	19941018
	JP 09504525	T	19970506	JP 1994-512182	19941018
	EP 813414	A1	19971229	EP 1994-931923	19941018
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, ST, LT				
	FI 9601681	A	19960612	FI 1996-1681	19960417
	NO 9601536	A	19960618	NO 1996-1536	19960418
	LV 11432	B	19961220	LV 1996-124	19960423
PRAI	US 1993-139296	A	19931019		
	US 1994-259091	A	19940613		
	WO 1994-US11912	W	19941018		

OS MARPAT 123:74929
TI ***159634-43-2***
BI: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of bisphosphonates and growth hormone secretagogues for treatment of osteoporosis, and their prepn.)
RN 159634-43-2 CAPLUS
CN Propanamide, N-[(1R)-2-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-amino-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 154 in file .gra /

OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 53 OF 53 CAPLUS COPYRIGHT 2011 ACS on STN
GI

/ Structure 155 in file .gra /

AB The title compds. [I; A = (un)substituted alkylene; B, D, E, F =

(un)substituted CH2, O, C:O, S(O)m, etc.; m = 0-2; R1 = (un)substituted alkyl, aryl, cycloalkyl, etc.; R2 = H, C1-6 alkyl, C3-7 cycloalkyl; R3a, R3b = H, halogen, C1-6 alkyl, OR2, CN, etc.; R4, R5 = H, (un)substituted C1-6 alkyl; R6 = H, C1-6 alkyl; n = 1, 2]. [ITI: C, H, I, J = C, N, S, Cl, which promote the release of growth hormone (no data) are prepd. Thus, N-[1(R)-[(2',3'-dihydro-2-oxo-spiro[piperidine-4,4'(H)-quinolin]-1-yl)carbonyl]-2-(indol-3-yl)ethyl]-2-amino-2-methylpropanamide hydrochloride was prepd. in 7 steps from 1'-(tert-butyloxycarbonyl)spiro[1H-indene-1,4'-piperidine].

AN 1995:511384 CAPLUS <<LOGINID::20111010>>

DN 122:213945

OREF 122:39107a,39110a

TI Spiro piperidines and homologs which promote release of growth hormone

IN Chen, Meng-Hsin; Johnston, David B. R.; Nargund, Ravi P.; Patchett, Arthur A.; Tata, James R.; Yang, Lihu

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9413696	A1	19940623	WO 1993-US11038	19931115
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5536716	A	19960716	US 1993-147226	19931103
	US 5578593	A	19961126	US 1993-146848	19931103
	DE 176993	B1	19990831	DE 1993-3309331	19931115
	DE 2168512	C2	20010510	DE 1995-1133249	19931115
	SK 282166	B6	20011106	SK 1995-759	19931115
	FI 9502863	A	19950609	FI 1995-2863	19950609
	FI 95502863	A	19950609	FI 1995-2863	19950609
	NO 9502294	A	19950810	NO 1995-2294	19950609
	NO 95502295	A	19950810	NO 1995-2295	19950609
PRAI	US 1993-147226	A	19931103		
	US 1992-989322	A	19921211		
	US 1993-146848		19931103		
	WO 1993-US11038	W	19931115		
	WO 1993-US11137	W	19931115		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 122:213945

TT ***159634-43-2***

PT: PCT (Reactant); RACT (Reactant or reagent)

(growth hormone release promoter)

RN 159634-43-2 CAPLUS

CN Propanamide, N-[(1R)-2-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-amino-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 156 in file .gra /

TT ***159633-96-2P***

PT: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, for growth hormone release promotion)

RN 159633-96-2 CAPLUS

CN Propanamide, N-[2-(1-acetyl-1,2-dihydrospiro[3H-indole-3,4'-piperidin]-1'-yl)-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-2-amino-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

/ Structure 157 in file .gra /

OSC G 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (41 CITINGS)
RE CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	55.72	751.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.83	-19.14

FILE 'STNGUIDE' ENTERED AT 15:14:31 ON 10 OCT 2011

FILE CONTAINS CURRENT INFORMATION
LAST RELOADED: Oct 7, 2011 (20111007/UP).